BioAtla, Inc. (BCAB)
Nasdaq · Healthcare · Biotechnology
$2.00+6.95%as of Nov 5, 2026, 7:50 AM ET
- Market cap
- $3.3M
- 52-week range
- $1.07 – $71.50
- 52-week change
- −93.75%
- EPS (trailing)
- −$25.23
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$59.6M
- Diluted EPS
- −$50.66
From the company’s annual report on SEC EDGAR.
About BioAtla, Inc.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Headquarters: San Diego, United States · 41 employees · bioatla.com